Bought the Dip in Credo: Aggressive Long After the Post-Earnings Flush

Hook & thesis

I doubled down aggressively on Credo Technology (CRDO) after a brutal washout. The company just reported hypergrowth numbers—Q1 revenue of $479 million, up 114.7% year-over-year—and yet the stock took a bath as investors focused on margin compression, elevated stock-based compensation and dilution fears. That selloff carved out a tactical buying window: the share price is now $152.69 after a single-day gap down from $162.95 (-10.26% versus the prior close), putting the chart into oversold territory (RSI ~30).

My thesis is simple and conditional: Credo is a pure-play high-speed connectivity supplier for AI data centers, and the secular demand for higher bandwidth and near-package optics is structural. The company’s top-line growth and free cash flow ($312.476 million) give it the runway to scale optical product lines. I am long because the underlying business momentum is intact, the balance sheet is healthy (current ratio ~7.4, quick ratio ~5.82) and the market’s reaction has been overly binary—punishing any near-term margin noise despite massive revenue acceleration. This trade is aggressive; I’m accepting volatility for asymmetric upside toward $280 over the next 180 trading days, with a hard stop at $118.

What Credo does and why the market should care

Credo Technology builds connectivity solutions for data infrastructure: SerDes chiplets, integrated circuits and active electrical cables designed to link GPUs, compute nodes and optics inside hyperscale AI clusters. In plain terms, Credo supplies the "plumbing" that lets massive GPU farms talk to each other at the speeds required for modern AI workloads.

Why that matters now: hyperscale customers are moving to higher-speed interfaces and near-package optics to scale AI clusters efficiently. Credo has been one of the direct beneficiaries of that shift. The company reported Q1 revenue of $479 million (up 114.7% YoY) and management expects optical revenue to surpass $600 million in FY2027 with multiple $100+ million product lines contributing—numbers that suggest Credo is capturing a meaningful slice of an expanding market.

Key recent facts and the case for accumulation

• Current market price: $152.69 (previous close $162.95; intraday weakness left the stock trading down roughly 10%).
• Market cap: roughly $28.2 billion; enterprise value ~ $27.74 billion.
• Valuation multiples are rich relative to historical tech norms: P/E ~ 65x and price-to-sales ~ 20.48x. EV/sales ~ 20.15x.
• Profitability and cash flow: GAAP net margins have been strong (news cited ~35.4% net margins in commentary), EPS is roughly $2.30 and free cash flow was about $312.476 million.
• Balance sheet liquidity: strong operating liquidity metrics (current ratio ~ 7.4, quick ratio ~ 5.82), and a low debt-to-equity reported as 0.
• Technicals: the 10/20/50-day moving averages are well above the current price, RSI ~ 30.10, MACD showing bearish momentum—but short interest and short volume spikes suggest a crowded trade on both sides, which amplifies intraday moves.

Valuation framing - expensive, but not irrational for growth

At face value Credo trades at premium multiples: market cap ~$28.2B and price-to-sales ~20x imply very high expectations. That premium is driven by extraordinary revenue growth: annual revenue has ramped from ~$436.8 million to roughly $1.3 billion in the last reported twelve months (company commentary) and Q1 growth of 114.7% YoY shows acceleration, not deceleration.

Put another way: the market has priced Credo like a high-growth software franchise rather than a connectivity hardware supplier. That’s the double-edged sword. If Credo hits its optical ramp targets and preserves mid-to-high 60%-plus gross margins at scale, the valuation can be justified. If margins compress meaningfully while growth slows, the multiple will re-rate lower quickly. My trade assumes the former scenario plays out over the next 180 trading days, or that the market begins to revalue Credo more on growth and cash flow than on short-term margin volatility.

Catalysts I’m watching

• Optical revenue ramp commentary and product cadence: management guided optical revenue to exceed $600 million in FY2027—any confirmation (product shipments, customer wins) will be a multi-quarter re-rating catalyst.
• Quarterly results and gross-margin trajectory: sequential stabilization or improvement in GAAP gross margins (they fell to ~64.5% from 68% in the most recent quarter) will remove a major investor overhang.
• Customer diversification: announcements that reduce customer concentration (today three customers account for a large share of revenue) will materially lower perceived customer risk.
• Continued free-cash-flow generation and controlled dilution: sustained FCF and clarity around stock-based compensation will calm valuation concerns.
• Peer and industry data-center spend proof points: broader confirmation that hyperscalers are accelerating spend on optics and high-speed connectivity will lend multiple expansion tailwinds.

Trade plan (actionable)

I opened a larger-than-usual long position at $152.69. My position is sized to tolerate elevated volatility; this is not a core buy for a conservative portfolio. The precise trade parameters are:

Why 180 trading days? The optical product ramps, enterprise ordering cycles and margin normalization usually play out over multiple quarters. I want enough runway for supply chain, qualification and customer adoption to show up in financials and commentary. If Credo prints one or two sequential quarters that confirm the optical ramp and a stable gross margin band, the path to $280 is plausible as multiple expansion returns alongside continued growth.

Risks and counterarguments

• Customer concentration: roughly three customers account for a very large share of revenue. If one cuts orders, top-line growth could decelerate sharply.
• Valuation sensitivity: at ~65x earnings and >20x sales, the stock is priced for near-perfect execution. Misses on margin or growth would amplify downside.
• Margin pressure and dilution: recent declines in GAAP gross margins (to ~64.5% from 68%) and elevated stock-based comp were cited as reasons for the selloff on 09/03/2026; further margin deterioration would be punitive.
• Execution risk on optical ramp: moving into optical at scale requires capital, supply-chain coordination and multi-customer qualification. Delays are possible and would push out valuation realization.
• High volatility and short activity: short interest and recent spikes in short volume make intraday and multi-day whipsaws likely; position sizing and a firm stop are essential.
• Macro/AI spend cycles: hyperscaler capital allocation can be lumpy; a broader pullback in AI capex would hurt Credo despite structural demand.

Counterargument: The simplest bearish case is that investors were right to punish the stock: margins are compressing, dilution pushes forward true earnings multiples higher, and valuation is disconnected from reasonable comparables. From that view, waiting for a calmer, margin-stabilized setup or buying on a much lower multiple after a second leg down is a prudent strategy instead of averaging up into volatility.

What would change my mind

I would materially reduce exposure if any of the following occur: (1) the next quarter shows another sequential decline in gross margin without evidence of offsetting leverage or volume benefits; (2) management revises up stock-based compensation dilution meaningfully or signals the need for equity raises; (3) there are signs of significant volume pull-through failure at its top three customers; or (4) macro AI capex shows a sustained retrenchment across multiple hyperscalers.

Conclusion

Credo’s post-earnings crash delivered an asymmetric opportunity: a company growing into the scale phase of optical and high-speed connectivity with positive free cash flow and a clean balance sheet, but priced for perfection. I doubled down because I believe the path to near-term product ramps and margin stabilization is intact—and because a disciplined stop at $118 controls the downside if execution falters. This is an aggressive, high-volatility trade for patient traders who can stomach swings while waiting for multi-quarter execution to validate the story.

Final checklist

• Entry: $152.69 - execute in tranches to avoid adverse fills.
• Stop: $118 - strict and non-negotiable for this sized position.
• Target: $280 by 180 trading days - based on re-rating plus continued top-line outperformance and optical revenue ramping.
• Position-sizing: keep exposure limited to a small percentage of total portfolio (given high beta and valuation).

I’m long and doubled down—this trade is about backing execution in a structural market while respecting the sharp downside risks. Stay nimble and let the data (margins, revenue cadence, customer diversification) guide adjustments.